Listen
Reason for request
Following the request from the Directorate-General for Health received on 26 June 2012, the Committee is examining FLUENZ with a view to including it on the list of medicines approved for hospital use.
-
Clinical Benefit
| Substantial |
The actual benefit of FLUENZ is substantial in populations from 24 months to under 18 years old recommended by the French High Council for Public Health (Haut Conseil de la santé publique). |
Clinical Added Value
| no clinical added value |
The Committee considers that FLUENZ, administered intranasally, does not provide an improvement in actual benefit (IAB V) in the prevention of influenza in patients aged 24 months old to under 18 years old recommended by the French High Council for Public Health compared to injectable inactivated influenza vaccines. |
Documents
English version
Contact Us
Évaluation des médicaments
